Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
- PMID: 8996210
Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
Abstract
This study tests the hypothesis that adenosine A2 receptor activation reduces reperfusion injury by inhibiting neutrophils in a canine model of ischemia and reperfusion. In 16 anesthetized, open-chest dogs, the left anterior descending coronary artery was ligated for 60 min and reperfused for 3 hr. An intracoronary infusion of either the selective adenosine A2 agonist CGS-21680 at 0.2 microgram/kg/min (n = 8) or vehicle (n = 8) was started 5 min before reperfusion and discontinued after 60 min. The area at risk was comparable between vehicle-treated and CGS-21680-treated groups (39.6 +/- 4.1 vs. 37.1 +/- 2.5% of left ventricle). Infarction size, determined with triphenyltetrazolium chloride, was smaller in the CGS-21680-treated group than in the vehicle-treated group (15.4 +/- 2.9 vs. 29.8 +/- 2.3% of area at risk, P < .05 vs. vehicle-treated group). CGS-21680 significantly reduced neutrophil accumulation (myeloperoxidase activity) in the nonnecrotic area at risk tissue, compared with the vehicle-treated group (2.12 +/- 0.5 vs. 6.47 +/- 0.6 U/g of tissue, P < .05 vs. vehicle-treated group). In in vitro studies, CGS-21680 reduced platelet-activating factor (PAF)-activated canine neutrophil adherence to the endothelial surface of normal homologous coronary artery segments. Compared with PAF-stimulated neutrophils (188.4 +/- 9.4 adhered neutrophils/mm2), CGS-21680 reduced adherence close to base-line levels (46.6 +/- 5.8 adhered neutrophils/mm2) at concentrations of 10 microM (65.6 +/- 8.2 adhered neutrophils/mm2, P < .05 vs. PAF-stimulated group) and 50 microM (56.6 +/- 4.6 adhered neutrophils/mm2, P < .05 vs. PAF-stimulated group). Superoxide anion production (cytochrome c reduction) by activated neutrophils was reduced by CGS-21680 from 33.8 +/- 5.0 to 8.9 +/- 3.6 nmol/5 min/5 x 10(5) cells (P < .05 vs. PAF-stimulated group). We conclude that specific A2 receptor stimulation with CGS-21680 at reflow reduces reperfusion injury by inhibiting neutrophil-related processes.
Similar articles
-
Blood cardioplegia supplementation with the sodium-hydrogen ion exchange inhibitor cariporide to attenuate infarct size and coronary artery endothelial dysfunction after severe regional ischemia in a canine model.J Thorac Cardiovasc Surg. 2003 Jan;125(1):155-64. doi: 10.1067/mtc.2003.65. J Thorac Cardiovasc Surg. 2003. PMID: 12538999
-
Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization.J Thorac Cardiovasc Surg. 2000 Aug;120(2):350-8. doi: 10.1067/mtc.2000.107281. J Thorac Cardiovasc Surg. 2000. PMID: 10917953
-
Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion.J Surg Res. 1993 Nov;55(5):504-15. doi: 10.1006/jsre.1993.1176. J Surg Res. 1993. PMID: 8231170
-
Mechanisms and therapy of myocardial reperfusion injury.Circulation. 1990 Mar;81(3 Suppl):IV69-78. Circulation. 1990. PMID: 2407376 Review.
-
Neutrophil-endothelial interactions: modulation of neutrophil activation responses by endothelial cells.Tissue Cell. 1987;19(5):99-606. Tissue Cell. 1987. PMID: 2827343 Review.
Cited by
-
Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration.Purinergic Signal. 2012 Sep;8(3):523-37. doi: 10.1007/s11302-011-9282-3. Epub 2011 Dec 6. Purinergic Signal. 2012. PMID: 22143354 Free PMC article. Review.
-
ATL 313, A Selective A(2A) Adenosine Receptor Agonist, Reduces Myocardial Infarct Size in a Rat Ischemia/Reperfusion Model.Open Cardiovasc Med J. 2009 Nov 25;3:166-72. doi: 10.2174/1874192400903010166. Open Cardiovasc Med J. 2009. PMID: 20111666 Free PMC article.
-
Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1183-9. doi: 10.1152/ajpheart.00264.2011. Epub 2011 Jul 8. Am J Physiol Heart Circ Physiol. 2011. PMID: 21743001 Free PMC article.
-
Adenosine myocardial protection: preliminary results of a phase II clinical trial.Ann Surg. 1999 May;229(5):643-9; discussion 649-50. doi: 10.1097/00000658-199905000-00006. Ann Surg. 1999. PMID: 10235522 Free PMC article. Clinical Trial.
-
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.Pharmacol Rev. 2001 Dec;53(4):527-52. Pharmacol Rev. 2001. PMID: 11734617 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials